Fintel reports that on January 6, 2025, Cantor Fitzgerald initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a Overweight ...

Cantor Fitzgerald reiterated their overweight rating on shares of TeraWulf (NASDAQ:WULF – Free Report) in a research report released on Monday,Benzinga reports. Cantor Fitzgerald currently has a ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Goldman has recently initiated Esperion Therapeutics Inc (ESPR) stock to Neutral rating, as announced on December 18, 2024, according to Finviz. Earlier, on December 17, 2024, Cantor Fitzgerald had ...

The general mood among these heavyweight investors is divided, with 51% leaning bullish and 44% bearish. Among these notable ...

Rivian reports 14,183 EV deliveries in December quarter, analysts react. Cantor Fitzgerald reiterates Overweight with $13 ...

Ladenburg Thalmann has recently reduced SoundHound AI Inc (SOUN) stock to Neutral rating, as announced on November 13, 2024, according to Finviz. Earlier, on August 9, 2024, Cantor Fitzgerald had ...

Equities research analysts at Cantor Fitzgerald started coverage on shares of Atyr PHARMA (NASDAQ:ATYR – Get Free Report) in a research report issued to clients and investors on Monday,Briefing.com ...

Cantor Fitzgerald initiated coverage of aTyr Pharma (ATYR) with an Overweight rating. aTyr Pharma’s lead drug Efzofitimod is in two trials for ...

Cantor Fitzgerald analyst Kristen Kluska initiated coverage of Supernus (SUPN) with an Overweight rating and $57 price target Don't Miss Our ...

The stock market is taking a breather after a relentless run, but opportunities still abound, according to some on Wall ...